Argus II is a novel healthcare technology that restores vision in RP patients. Improvements in visual acuity are expected to lead to improvements in patient self-confidence, decreasing their ...
Second Sight Medical Products, Inc. Receives FDA Approval for the Argus 2s Retinal Prosthesis System
LOS ANGELES--(BUSINESS WIRE)-- Second Sight Medical Products (NASDAQ:EYES) a leading developer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful ...
SYLMAR, Calif.--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are ...
The Argus II, a “bionic eye”, is intended to provide electrical stimulation of the retina to elicit visual perception in blind subjects with severe to profound retinitis pigmentosa, according to the ...
CPT copyright 2013 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association. CMS has approved Second Sight ...
Second Sight Medical, a healthcare products company based in Sylmar, California, announced that it received approval from the United States Food and Drug Administration for its Argus II Retinal ...
Second Sight Medical shares jumped to nearly $10 after the FDA approved its Argus2 Retinal Prosthesis System. The regulatory approval arrives as Second Sight works to complete a business combination ...
SYLMAR, Calif.--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are ...
Argus II Retinal Prosthesis fitted patients incurred a discounted incremental cost of 42,455 Euros in comparison to the patient given 'CAU' over the 25 years of time. Progressive improvement in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback